Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Aug 8:11:184.
doi: 10.1186/1479-5876-11-184.

Assessment of risk of bias in translational science

Affiliations

Assessment of risk of bias in translational science

Andre Barkhordarian et al. J Transl Med. .

Abstract

Risk of bias in translational medicine may take one of three forms: A. a systematic error of methodology as it pertains to measurement or sampling (e.g., selection bias), B. a systematic defect of design that leads to estimates of experimental and control groups, and of effect sizes that substantially deviate from true values (e.g., information bias), and C. a systematic distortion of the analytical process, which results in a misrepresentation of the data with consequential errors of inference (e.g., inferential bias). Risk of bias can seriously adulterate the internal and the external validity of a clinical study, and, unless it is identified and systematically evaluated, can seriously hamper the process of comparative effectiveness and efficacy research and analysis for practice. The Cochrane Group and the Agency for Healthcare Research and Quality have independently developed instruments for assessing the meta-construct of risk of bias. The present article begins to discuss this dialectic.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Schematic representation of the meta-construct of translational health care in general, and translational medicine in particular, which consists of two fundamental constructs: the T1 “block” (as per Institute of Medicine's Clinical Research Roundtable nomenclature), which represents the transfer of new understandings of disease mechanisms gained in the laboratory into the development of new methods for diagnosis, therapy, and prevention as well as their first testing in humans, and the T2 “block”, which pertains to translation of results from clinical studies into everyday clinical practice and health decision making [[3]]. The two “blocks” are inextricably intertwined because they jointly strive toward patient-centered research outcomes (PCOR) through the process of comparative effectiveness and efficacy research/review and analysis for clinical practice (CEERAP). The domain of each construct is distinct, since the “block” T1 is set in the context of a laboratory infrastructure within a nurturing academic institution, whereas the setting of “block” T2 is typically community-based (e.g., patient-centered medical/dental home/neighborhoods [4]; “communities of practice” [5]).
Figure 2
Figure 2
Proportion of shared variance in criterion validity (A) and inter-rater reliability (B) in the AHRQ Risk of Bias instrument revised as described. Two raters were trained and standardized [20] with the revised AHRQ Risk of Bias and with the R-Wong instrument, which has been previously validated [24]. Each rater independently produced ratings on a sample of research reports with both instruments on two separate occasions, 1–2 months apart. Pearson correlation coefficient was used to compute the respective associations. The figure shows Venn diagrams to illustrate the intersection between each two sets data used in the correlations. The overlap between the sets in each panel represents the proportion of shared variance for that correlation. The percent of unexplained variance is given in the insert of each panel.

Similar articles

Cited by

References

    1. Jiang F, Zhang J, Wang X, Shen X. Important steps to improve translation from medical research to health policy. J Trans Med. 2013;11:33. doi: 10.1186/1479-5876-11-33. - DOI - PMC - PubMed
    1. Sung NS, Crowley WF Jr, Genel M, Salber P, Sandy L, Sherwood LM, Johnson SB, Catanese V, Tilson H, Getz K, Larson EL, Scheinberg D, Reece EA, Slavkin H, Dobs A, Grebb J, Martinez RA, Korn A, Rimoin D. Central challenges facing the national clinical research enterprise. JAMA. 2003;289:1278–1287. doi: 10.1001/jama.289.10.1278. - DOI - PubMed
    1. Woolf SH. The meaning of translational research and why it matters. JAMA. 2008;299(2):211–213. doi: 10.1001/jama.2007.26. - DOI - PubMed
    1. Chiappelli F. From translational research to translational effectiveness: the “patient-centered dental home” model. Dental Hypotheses. 2011;2:105–112. doi: 10.5436/j.dehy.2011.2.00035. - DOI
    1. Maida C. In: Comparative effectiveness and efficacy research and analysis for practice (CEERAP): applications for treatment options in health care. Chiappelli F, Brant X, Cajulis C, editor. Heidelberg: Springer–Verlag; 2012. Building communities of practice in comparative effectiveness research. Chapter 1.

Publication types

LinkOut - more resources